Publications by authors named "J Uchino"
Background: Although concurrent chemoradiotherapy (CCRT) followed by durvalumab is the standard treatment for patients with stage III non-small cell lung cancer (NSCLC), only half of the patients are allowed to receive CCRT in real-world settings. We evaluated the efficacy and safety of durvalumab after radiation monotherapy for NSCLC patients who are ineligible for chemoradiotherapy.
Methods: A single-arm, prospective, open-label, multicenter phase II trial was conducted in Japan.
Background: The combination of erlotinib, a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and ramucirumab, an anti-vascular endothelial growth factor receptor (VEGFR) antibody, is one of the most effective treatments for patients with non-small cell lung cancer (NSCLC) and mutation. However, little is known about the safety and efficacy of this combination treatment for patients with brain metastases.
Methods: This single arm, prospective, open-label, multicenter, phase II study will recruit 32 NSCLC patients with mutation (except for T790M mutation) and brain metastases (asymptomatic or mild symptoms).
Article Synopsis
- Dacomitinib shows better outcomes than gefitinib for NSCLC patients with EGFR mutations but often causes skin toxicities that can lead to treatment stopping.
- A study involving 41 Japanese patients tested a strategy to prevent these skin issues while they were treated with dacomitinib, focusing on managing Grade ≥2 skin toxicities in the first 8 weeks.
- While the skin toxicity prevention approach was not particularly effective, patients were mostly compliant with their medication, highlighting the need for better patient education to help with continuity in treatment.
Background: Ramucirumab plus docetaxel combination therapy (DOC/RAM) for advanced non-small cell lung cancer (NSCLC) achieves favorable outcomes; however, efficacy and safety for patients with brain metastases are still unclear.
Methods: Eligible patients included those with advanced NSCLC with measurable asymptomatic brain metastases that progressed after chemotherapy. Patients were intravenously administered ramucirumab (10 mg/kg) and docetaxel (60 mg/m2) every 21-day cycle.
During hemodialysis (HD), blood pressure (BP) changes are frequently observed. However, the mechanism of BP changes during HD has not been fully clarified. The cardio-ankle vascular index (CAVI) reflects the arterial stiffness of the arterial tree from the origin of the aorta to the ankle independent from BP during measurement.
View Article and Find Full Text PDF